Century Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Philadelphia, PA
IPSC chart
What traders are saying about $IPSC
Latest postsCentury Therapeutics, Inc. news
- Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
Yahoo Finance ·
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Yahoo Finance ·
- Century Therapeutics Appoints Joseph Truitt to Board of Directors
Yahoo Finance ·
- Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Yahoo Finance ·
- Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
Yahoo Finance ·
- Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Yahoo Finance ·
- Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
Yahoo Finance ·
- Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
Yahoo Finance ·
- Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
Yahoo Finance ·
- New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Yahoo Finance ·
- Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Yahoo Finance ·
- Century Therapeutics Reports First Quarter Financial Results and Business Updates
Yahoo Finance ·
Century Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M |
| Diluted EPS | $-0.14 | $-1.61 | $-2.30 | $-2.96 |
| Total assets (year end) | $223.7M | $353.2M | $360.7M | $486.5M |
| Cash and equivalents (year end) | $61.9M | $58.4M | $47.3M | $84.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Century Therapeutics, Inc.
- Ticker
- IPSC (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Philadelphia, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1850119
Frequently asked questions
What exchange is Century Therapeutics, Inc. listed on?
Century Therapeutics, Inc. trades on the Nasdaq under the ticker symbol IPSC.
What industry is Century Therapeutics, Inc. in?
Century Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Century Therapeutics, Inc. headquartered?
Century Therapeutics, Inc.'s business address on file with the SEC is in Philadelphia, PA.
When does Century Therapeutics, Inc.'s fiscal year end?
Century Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Century Therapeutics, Inc. report?
Century Therapeutics, Inc. reported $109.2M in revenue for calendar year 2025, according to its SEC filings.